Verily is a health-technology and platform company purpose-built for precision health, combining deep clinical, regulatory, and technological expertise. Originally a moonshot project within Google X, it operates as a subsidiary of Alphabet Inc. and has a venture arm (Verily Ventures) that invests in early-stage life sciences and digital health companies.
Their most common stage is series-c (71% of deals). Average disclosed round size is $296.7M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series C
Last 12 Mo
0
Team
Bharat Rajagopal
Chief Revenue Officer
Laura O’Donnell
Chief Legal Officer
Scott Burke
Chief Technology Officer
Stephen Gillett
Chairman and CEO
Vindell Washington
Chief Physician Executive
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Syllable | Series C | $40M | Jun 2021 |
 Genalyte | Series C | $50M | Jan 2021 |
 EQRx | Growth | $1.8B | Jan 2021 |
| CCiitizen | Series A | $17M | Jan 2019 |
| FForward Health | Series C | $65M | Jan 2018 |
 Freenome Inc | Series C | $65M | Mar 2017 |
| SSyllable Corporation | Series C | $40M | — |
Top Co-Investors
TCV2 shared
Oak HC/FT2 shared
Andreessen Horowitz2 shared
GV1 shared
Khosla Ventures1 shared
Redmile Group1 shared
HBM Healthcare Investments1 shared
Provenio Capital1 shared
Casdin Capital1 shared
Mubadala Investment Company1 shared
Franklin Templeton1 shared
BVF Partners L.P.1 shared
Boxer Capital1 shared
Mubadala Ventures1 shared
Bain Capital Life Sciences1 shared
Avidity Partners1 shared
Rock Springs Capital1 shared
The Invus Group, LLC1 shared
Founders Fund1 shared
Last updated: 9 September 2026